Quote (mki @ Nov 20 2022 11:14am)
From what I understand:
The immune system cells they rerprogrammed were outside of the body, which should eliminate many of the problems with CRISPR.
I don't know if that answers your question.
I get why they did it ex-vivo and reimplanted the cells, but you can still get random off-target cuts with CRISPR across the genome leading to unpredictable effects once they reintroduce it in the body. What they're proposing will also be fairly expensive but its a cool paper. Each treatment is going to end up being an N=1 since they're sequencing tumors to find unique mutations to target.
Edit: Also looking at the abstract/author interviews, the treatment didn't work. They claim they need higher doses so if there's any chance of complications/off-target effects you'll see it there. They likely picked a dose in line with some theoretical MABEL level since this is so novel.
Also it isn't a vaccine, its just a treatment since you need to have cancer first before they can design their CRISPR guides
This post was edited by Sioux on Nov 20 2022 01:21pm